Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists for mental health treatments, announced that co-founders Eric So and Paul Glavine have stepped down from their executive and consulting roles while retaining their positions on the company’s board of directors. So previously served as president and executive chairman, while Glavine served as chief growth officer. The company also appointed Mark Lawson as independent chair of the board, effective immediately, and named So chairman emeritus.
Lawson, who has served on the board since November 2020, brings more than 20 years of private equity and investment banking experience. The leadership changes follow the recent appointment of Michael Halstead as CEO and are intended to support the company’s next stage of development. Both co-founders expressed confidence in the current leadership team and will continue supporting Helus Pharma through their board positions.
The transition matters because Helus Pharma is advancing late-stage clinical programs that could address major unmet needs in mental health. The company remains focused on advancing its HLP003 and HLP004 clinical programs and continues to anticipate reporting topline data from its Phase 3 APPROACH pivotal study of HLP003 for major depressive disorder in the fourth quarter of 2026. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the adjunctive treatment of major depressive disorder, while HLP004 is in Phase 2 for generalized anxiety disorder. A stable board and experienced leadership are critical as the company moves toward pivotal data readouts.
Helus Pharma(TM), the commercial operating name of Cybin Inc., founded in 2019, is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs – novel serotonergic agonists: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The Company’s proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions. With class leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. The Company operates in Canada, the United States, the United Kingdom and Ireland. For Company updates and to learn more about Helus Pharma, visit www.helus.com.
The announcement was disseminated by TinyGems, a specialized communications platform focused on innovative small-cap and mid-cap companies. TinyGems is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which provides access to wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. For full terms and disclaimers, see https://www.TinyGems.com/Disclaimer.
